| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 13 | 2014 | 705 | 1.000 |
Why?
|
| Heart Failure | 14 | 2017 | 1204 | 0.960 |
Why?
|
| Heart-Assist Devices | 8 | 2017 | 731 | 0.510 |
Why?
|
| Stroke Volume | 5 | 2015 | 456 | 0.510 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2014 | 152 | 0.490 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2014 | 19 | 0.480 |
Why?
|
| Amyloidosis | 1 | 2014 | 115 | 0.430 |
Why?
|
| Cardiomyopathies | 2 | 2014 | 240 | 0.420 |
Why?
|
| Superior Vena Cava Syndrome | 2 | 2010 | 16 | 0.420 |
Why?
|
| Vena Cava, Superior | 2 | 2010 | 59 | 0.400 |
Why?
|
| Stents | 3 | 2010 | 377 | 0.390 |
Why?
|
| Angioplasty | 1 | 2010 | 70 | 0.360 |
Why?
|
| Heart Failure, Diastolic | 1 | 2008 | 2 | 0.340 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2014 | 80 | 0.300 |
Why?
|
| Heart Diseases | 3 | 2010 | 290 | 0.290 |
Why?
|
| Kidney Diseases | 2 | 2008 | 418 | 0.260 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2008 | 231 | 0.250 |
Why?
|
| Renin-Angiotensin System | 3 | 2014 | 133 | 0.230 |
Why?
|
| Graft Rejection | 3 | 2014 | 1065 | 0.230 |
Why?
|
| Kidney | 1 | 2008 | 1241 | 0.220 |
Why?
|
| Receptors, Adrenergic, beta | 2 | 2014 | 72 | 0.210 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2013 | 130 | 0.200 |
Why?
|
| Family Practice | 1 | 2001 | 84 | 0.190 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2001 | 59 | 0.190 |
Why?
|
| Hypertension | 1 | 2008 | 1141 | 0.180 |
Why?
|
| Point-of-Care Systems | 2 | 2015 | 141 | 0.170 |
Why?
|
| Middle Aged | 22 | 2017 | 25028 | 0.160 |
Why?
|
| Humans | 35 | 2017 | 86643 | 0.160 |
Why?
|
| Echocardiography | 5 | 2005 | 911 | 0.160 |
Why?
|
| Malignant Carcinoid Syndrome | 1 | 1997 | 4 | 0.160 |
Why?
|
| Liver Transplantation | 3 | 2008 | 1268 | 0.160 |
Why?
|
| Primary Health Care | 1 | 2001 | 339 | 0.150 |
Why?
|
| Jugular Veins | 1 | 1997 | 69 | 0.150 |
Why?
|
| Carcinoid Heart Disease | 1 | 1996 | 2 | 0.140 |
Why?
|
| Male | 25 | 2015 | 40965 | 0.140 |
Why?
|
| Biopsy | 2 | 2014 | 1163 | 0.140 |
Why?
|
| Hemodynamics | 3 | 2013 | 710 | 0.140 |
Why?
|
| Ambulatory Care | 2 | 2015 | 181 | 0.130 |
Why?
|
| Heart Ventricles | 3 | 2012 | 760 | 0.130 |
Why?
|
| Cardiovascular Diseases | 2 | 2005 | 827 | 0.130 |
Why?
|
| Cardiac Volume | 1 | 2015 | 53 | 0.130 |
Why?
|
| Tricuspid Valve | 2 | 2006 | 96 | 0.130 |
Why?
|
| Adult | 17 | 2017 | 25648 | 0.130 |
Why?
|
| Receptors, Adrenergic | 1 | 2014 | 15 | 0.120 |
Why?
|
| Prosthesis-Related Infections | 1 | 2014 | 58 | 0.120 |
Why?
|
| Digoxin | 1 | 2014 | 21 | 0.120 |
Why?
|
| Cardiac Catheterization | 2 | 2013 | 291 | 0.120 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2014 | 35 | 0.120 |
Why?
|
| Efferent Pathways | 1 | 2014 | 21 | 0.120 |
Why?
|
| Prealbumin | 1 | 2014 | 34 | 0.120 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2014 | 25 | 0.120 |
Why?
|
| Tricuspid Valve Insufficiency | 2 | 2006 | 111 | 0.120 |
Why?
|
| Exercise Tolerance | 1 | 2014 | 48 | 0.120 |
Why?
|
| Reoperation | 2 | 2013 | 597 | 0.120 |
Why?
|
| Vena Cava, Inferior | 1 | 2015 | 143 | 0.120 |
Why?
|
| Reflex | 1 | 2014 | 79 | 0.120 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2013 | 16 | 0.120 |
Why?
|
| Amyloid | 1 | 2014 | 85 | 0.120 |
Why?
|
| Afferent Pathways | 1 | 2014 | 77 | 0.120 |
Why?
|
| Norepinephrine | 1 | 2014 | 167 | 0.120 |
Why?
|
| Sympathetic Nervous System | 1 | 2014 | 104 | 0.120 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2013 | 16 | 0.120 |
Why?
|
| Cardiotonic Agents | 1 | 2014 | 87 | 0.120 |
Why?
|
| Exercise Therapy | 1 | 2014 | 80 | 0.120 |
Why?
|
| Forecasting | 1 | 2014 | 304 | 0.110 |
Why?
|
| Balloon Occlusion | 1 | 2012 | 27 | 0.110 |
Why?
|
| Phlebography | 2 | 2010 | 66 | 0.100 |
Why?
|
| Shock, Cardiogenic | 1 | 2012 | 95 | 0.100 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2013 | 162 | 0.100 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2013 | 139 | 0.100 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2013 | 187 | 0.100 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2013 | 103 | 0.100 |
Why?
|
| Fibrinolytic Agents | 1 | 2013 | 202 | 0.100 |
Why?
|
| Aortic Valve | 1 | 2013 | 222 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2014 | 447 | 0.100 |
Why?
|
| Thrombolytic Therapy | 1 | 2013 | 220 | 0.100 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2014 | 219 | 0.100 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 449 | 0.100 |
Why?
|
| Ventricular Function, Left | 2 | 2013 | 592 | 0.100 |
Why?
|
| Disease Progression | 2 | 2008 | 1531 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 376 | 0.090 |
Why?
|
| Pericardium | 1 | 2010 | 65 | 0.090 |
Why?
|
| Myocardium | 2 | 2010 | 529 | 0.090 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2005 | 318 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 819 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2014 | 535 | 0.090 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2002 | 97 | 0.090 |
Why?
|
| Prosthesis Design | 3 | 2017 | 278 | 0.090 |
Why?
|
| Aged | 11 | 2017 | 18415 | 0.090 |
Why?
|
| Postoperative Complications | 2 | 2010 | 2207 | 0.090 |
Why?
|
| Constriction, Pathologic | 1 | 2010 | 213 | 0.090 |
Why?
|
| Cardiomyopathy, Hypertrophic, Familial | 1 | 2008 | 4 | 0.090 |
Why?
|
| Calcinosis | 1 | 2010 | 224 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 509 | 0.080 |
Why?
|
| Ventricular Fibrillation | 1 | 2008 | 65 | 0.080 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2008 | 67 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 1384 | 0.080 |
Why?
|
| Diuretics | 1 | 2008 | 124 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 860 | 0.080 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 90 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2012 | 346 | 0.080 |
Why?
|
| Calcium Channel Blockers | 1 | 2008 | 203 | 0.080 |
Why?
|
| Thermodilution | 1 | 2007 | 21 | 0.070 |
Why?
|
| Female | 15 | 2015 | 44532 | 0.070 |
Why?
|
| Dexamethasone | 1 | 2007 | 326 | 0.070 |
Why?
|
| Coronary Artery Disease | 1 | 2010 | 350 | 0.070 |
Why?
|
| Nursing Assessment | 1 | 2005 | 20 | 0.070 |
Why?
|
| Coronary Stenosis | 1 | 2005 | 39 | 0.060 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2005 | 66 | 0.060 |
Why?
|
| Tissue Donors | 2 | 2006 | 463 | 0.060 |
Why?
|
| Prevalence | 1 | 2008 | 1239 | 0.060 |
Why?
|
| Catheterization | 2 | 2013 | 232 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2014 | 7993 | 0.060 |
Why?
|
| Brain | 1 | 2014 | 2216 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2010 | 971 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 1673 | 0.060 |
Why?
|
| Time Factors | 3 | 2014 | 5210 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2015 | 751 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 1204 | 0.060 |
Why?
|
| Septal Occluder Device | 2 | 2013 | 42 | 0.050 |
Why?
|
| Tricuspid Valve Stenosis | 1 | 2002 | 4 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2007 | 663 | 0.050 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2007 | 516 | 0.050 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2002 | 64 | 0.050 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2002 | 67 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 2008 | 849 | 0.050 |
Why?
|
| Arginine Vasopressin | 1 | 2001 | 47 | 0.050 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2001 | 39 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2015 | 695 | 0.050 |
Why?
|
| Age Distribution | 1 | 2001 | 204 | 0.050 |
Why?
|
| Physical Examination | 1 | 2001 | 149 | 0.050 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2013 | 344 | 0.050 |
Why?
|
| Angioplasty, Balloon | 1 | 2000 | 95 | 0.050 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2000 | 99 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2012 | 3640 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2010 | 3241 | 0.040 |
Why?
|
| United States | 3 | 2014 | 6672 | 0.040 |
Why?
|
| Heart Atria | 1 | 2000 | 250 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2014 | 8489 | 0.040 |
Why?
|
| Diastole | 2 | 2010 | 144 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 72 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 1169 | 0.040 |
Why?
|
| Prosthesis Failure | 1 | 2017 | 111 | 0.040 |
Why?
|
| Blood Volume Determination | 1 | 2015 | 14 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 1997 | 297 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 1997 | 328 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2012 | 2261 | 0.030 |
Why?
|
| Survival Rate | 2 | 2012 | 1863 | 0.030 |
Why?
|
| Ultrafiltration | 1 | 2013 | 13 | 0.030 |
Why?
|
| Jehovah's Witnesses | 1 | 2013 | 18 | 0.030 |
Why?
|
| Infusions, Parenteral | 1 | 2013 | 50 | 0.030 |
Why?
|
| Electrocardiography | 1 | 1996 | 478 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2013 | 68 | 0.030 |
Why?
|
| International Normalized Ratio | 1 | 2013 | 38 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2012 | 2705 | 0.030 |
Why?
|
| Pulsatile Flow | 1 | 2013 | 49 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2013 | 179 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2013 | 148 | 0.030 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2013 | 108 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 859 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 1991 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 999 | 0.020 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2010 | 22 | 0.020 |
Why?
|
| Critical Illness | 1 | 2012 | 294 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 1139 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1686 | 0.020 |
Why?
|
| Cardiac Myosins | 1 | 2008 | 18 | 0.020 |
Why?
|
| Quality of Life | 1 | 2017 | 1585 | 0.020 |
Why?
|
| Myosin Heavy Chains | 1 | 2008 | 88 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2010 | 272 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 504 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1019 | 0.020 |
Why?
|
| Chicago | 1 | 2013 | 1379 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2008 | 293 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 943 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 2007 | 66 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2010 | 464 | 0.020 |
Why?
|
| Fibrosis | 1 | 2008 | 203 | 0.020 |
Why?
|
| Stroke | 1 | 2017 | 965 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2008 | 331 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1801 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2008 | 458 | 0.020 |
Why?
|
| Ventriculography, First-Pass | 1 | 2005 | 2 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1996 | 2601 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2007 | 352 | 0.020 |
Why?
|
| Endocardium | 1 | 2005 | 76 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 2271 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 2767 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2004 | 90 | 0.020 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2004 | 36 | 0.020 |
Why?
|
| Graft Survival | 1 | 2008 | 884 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2004 | 123 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2006 | 397 | 0.020 |
Why?
|
| Prognosis | 1 | 2012 | 3679 | 0.010 |
Why?
|
| Illinois | 1 | 2005 | 462 | 0.010 |
Why?
|
| Risk Factors | 1 | 2014 | 5417 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2006 | 1538 | 0.010 |
Why?
|
| Biomarkers | 1 | 2008 | 1718 | 0.010 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2002 | 78 | 0.010 |
Why?
|
| Image Enhancement | 1 | 2005 | 563 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 2002 | 165 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2001 | 38 | 0.010 |
Why?
|
| Ventricular Dysfunction | 1 | 2001 | 28 | 0.010 |
Why?
|
| Heart Valve Diseases | 1 | 2001 | 109 | 0.010 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 1999 | 10 | 0.010 |
Why?
|
| Incidence | 1 | 2004 | 1577 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 1513 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 2000 | 187 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 2000 | 267 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2006 | 4213 | 0.010 |
Why?
|
| Mutation | 1 | 2008 | 3968 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2005 | 806 | 0.010 |
Why?
|
| Adolescent | 1 | 2006 | 8981 | 0.010 |
Why?
|